Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 6/9/08 → 6/8/15 |
Funding
- Frontier Science and Technology Research Foundation (PCOE2205SA-00 // E2205)
- Sanofi US Services Inc. (PCOE2205SA-00 // E2205)
ECOG PCO-RL: E2205 SA: A Randomized Phase II Study to Measure Response Rate and Toxicity of Neo-Adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Pat
- Yang, Ximing J (PD/PI)
Project: Research project